HER-2 enriched subtype predicts for HER2 blockade benefit with lapatinib and trastuzumab
Risk of chemotherapy-induced hair loss common to breast cancer therapy may be reduced with the use of scalp-cooling device.
Genome editing technology illustrates progression of normal blood cells to leukemia.
Outcomes improved with short-course radiation and delay to surgery of 4 to 8 weeks.
Treatment expectations of individuals with metastatic prostate cancer and their health care providers often do not match.